Medi-Cal dropping coverage Perhaps the most significant change for low-income populations was Medi-Cal, California Medicaid program, dropping GLP-1 weight loss coverage effective January 1, 2026
Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing
Semaglutide acts on appetite centers in the brain, particularly the hypothalamus, leading to decreased hunger and reduced food intake
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
To draw a 250 mcg dose you would fill the syringe to 10 units
These can include nausea, dizziness, or fatigue